Diagnosis of Postpartum Depression
Use the Edinburgh Postnatal Depression Scale (EPDS) as your primary screening tool, with a cutoff score of ≥10 for identifying possible postpartum depression, followed by clinical diagnostic interview using DSM-5 criteria for definitive diagnosis. 1
Recommended Screening Approach
The EPDS is the only patient-reported outcome measure that received a recommendation based on the COSMIN (Consensus-Based Standards for the Selection of Health Measurement Instruments) systematic evaluation of 10 validated screening tools 1. This tool demonstrated sufficient ratings for both structural validity and internal consistency, making it superior to alternatives like the Beck Depression Inventory, Patient Health Questionnaire-9, and Postpartum Depression Screening Scale 1.
EPDS Specifications:
- 10 questions covering the past 7 days
- Score range: 0-30
- Standard cutoff: ≥10 indicates possible depression 1
- Adjusted cutoff for high-risk populations: ≥7-9 may be more appropriate for low-income, urban mothers to improve sensitivity 2
- Timing: Can be administered weekly through 20 weeks postpartum and beyond 3
Alternative Ultra-Brief Screening
If time is severely limited, the EPDS-3 (anxiety subscale) demonstrates 95% sensitivity and 98% negative predictive value, identifying 16% more mothers with depression than the full EPDS 4. This 3-item version outperforms the 2-question Patient Health Questionnaire-style approach, which showed markedly inferior sensitivity (48-80%) 4.
Diagnostic Confirmation
Screening tools cannot diagnose postpartum depression—they identify women requiring further evaluation 1. A positive screen (EPDS ≥10) must be followed by:
- Structured Clinical Interview for DSM-5 (SCID-5) - the gold standard 1
- Clinical diagnosis by appropriately trained mental health professional using DSM-5 criteria for major depressive disorder 1
Optimal Screening Timing
Screen universally at multiple time points 5:
- During pregnancy (antenatal screening strongly recommended)
- 4 weeks postpartum (identifies 60% of women who will develop depression in first 20 weeks, and 80% who develop it within the first year) 3
- 6 weeks postpartum (traditional obstetric follow-up visit) 6
- Throughout the first postpartum year at well-child visits 2, 7
Universal screening significantly improves detection rates compared to risk-based screening alone 6, 7.
Key Risk Factors for Targeted Assessment
While universal screening is recommended, pay particular attention to women with 8:
- Personal psychiatric history (most potent single risk factor)
- Family psychiatric history (parents with psychiatric hospital contact or psychotropic medication use)
- Combined personal and family history (highest risk group: 11.7% absolute risk of mild/moderate PPD, with adjusted relative risk of 2.35) 8
- Previous postpartum depression episode 3
Screening Tool Alternatives and Their Limitations
If EPDS is unavailable 1:
- Patient Health Questionnaire-9 (PHQ-9): 9 items, past 2 weeks, cutoff ≥10 for moderate depression (but lower quality evidence than EPDS)
- Postpartum Depression Screening Scale (PDSS): 35 items, cutoff ≥80 (94% sensitivity, 98% specificity, but requires purchase)
- Beck Depression Inventory II: Optimal cutoff ≥14 for major depression in postpartum populations (lower than general population) 2
Critical Implementation Points
Common pitfalls to avoid:
- Using standard cutoff scores without considering population characteristics—low-income, urban mothers may require lower thresholds 2
- Screening without established systems for diagnostic follow-up and treatment referral 7
- Relying on screening alone without clinical interview for diagnosis 1
- Limiting screening to the immediate postpartum period—depression can develop throughout the first year 2, 3
For screening to improve clinical outcomes, it must be combined with:
- Accurate diagnostic assessment
- Strong collaborative relationships between primary care and mental health providers
- Longitudinal case management
- Assured appropriate treatment and follow-up 7
The EPDS takes minimal time to complete, is freely available, and has the strongest evidence base for postpartum populations, making it the clear choice for routine screening in obstetric, pediatric, and primary care settings 1.